HIV Clinical Trial
Official title:
Effectiveness of Mobile Phone Technology in Improving Adherence and Treatment Outcomes Among HIV Positive Patients on Antiretroviral Therapy (ART) in Malaysia
| Verified date | February 2016 |
| Source | Universiti Putra Malaysia |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The objective of this study was to determine the effectiveness of mobile phone technology (SMS and telephone call reminders) in improving adherence and treatment outcomes among HIV positive patients on ART in Malaysia.
| Status | Completed |
| Enrollment | 242 |
| Est. completion date | December 2014 |
| Est. primary completion date | December 2014 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 15 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - All HIV positive patients aged 15 - 65 years, assessed and eligible for ART commencement. - All ART eligible patients who have valid telephone numbers and can read text messages. Exclusion Criteria: - All HIV positive patients already commenced (current) or restarting ART due to previous default and/or lost-to-follow-up status - Pregnant HIV-positive ART patients - Foreigners |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Universiti Putra Malaysia | Ministry of Health, Malaysia |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Adherence (improved scheduled clinic attendance and medication adherence self-report) | Medication adherence was measured based on adherence ratio (for each of the 4 days prior was calculated as 1 minus (number of doses missed for the day/number of doses prescribed); adherence index based on formula adapted from Reynolds et al, 2007; and adherence category (>95% = Good adherence; 80-95% = Fair adherence; and <80% = Poor adherence) (WHO 2005). Scheduled clinic attendance was measured and categorized based on the number of scheduled clinic visits attended, number of times defaulted and whether or not the patient was lost-to-follow-up (a) Regular clinic attendee - a person who has never missed any scheduled clinic appointment (b) Defaulter - a person who has missed one or more scheduled clinic appointment, for any reason(s) (c) Lost-to-follow-up - a person is said to be lost to follow up if s/he refuses to show up for scheduled clinic visit for 3 consecutive months, after 3 consecutive attempts to track the client and bring them back on treatment. |
Change from baseline adherence at 3 months and at 6 months | |
| Secondary | Immunological (improved CD4 count) | cells per millimeter cube of blood | Change from baseline CD4 count at 6 months | |
| Secondary | Virological (decreased viral load) | absolute counts and log10 values. Viral suppression: (a) All clients with viral load <400 copies/mL at 6 months were termed to have achieved viral suppression, and (b) viral load >400 copies/mL at 6 months was termed unsuppressed viral load. | Change from baseline viral load at 6 months | |
| Secondary | Clinical (Improved weight) | weight in Kg | Change from baseline weight at 6months | |
| Secondary | Clinical (TB status) | TB status: (a) No signs and symptoms of TB (b) TB suspected clinically and referred for evaluation (c) Currently on INH Prophylaxis (IPT) (d) Currently on TB treatment. This was extracted onto the AACTG questionnaires from clinician's records based on clinical evaluation during hospital visits. Patient's susceptibility to, or recovery from TB was expected to correlate with immune status/recovery | Change from baseline TB status at 6 months | |
| Secondary | Clinical (Opportunistic infection index) | OI index: (a) WHO Clinical Stage 1 (b) WHO Clinical Stage 2 (c) WHO Clinical Stage 3 (d) WHO Clinical Stage 4. This was extracted onto the AACTG questionnaires from clinician's records based on clinical evaluation during hospital visits. Patient's susceptibility to, or recovery from OIs was expected to correlate with immune status/recovery | Change from baseline Opportunistic Infection (OI) index at 6 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
| Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
| Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
| Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
| Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
| Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
| Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
| Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
| Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
| Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
| Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
| Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
| Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
| Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
| Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
| Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
| Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
| Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
| Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |